I would agree that a US listing should be done from a position of strength. I don't think a US listing is a magic bullet but it can unlock huge value if done properly. To me before a US listing there needs to be a clear path forward both clinically and financially so that investors have strong, real reasons to embrace the new listing. The BTD should take care of the clinical path/optics and give investors a general target as to what a market cap for RVX should look like in relation to Apabetalone's market potential. Thus a clear idea of investment potential. A strong partnership with a BP would not only be a clear indication of financial viability but also a strong endorsement of Apabetalone and, again, the RVX investment proposition.

With a strong partnership and financing in place for the Apabetalone program, funds raised with a US listing could be used to bring forward other previously talked about programs/compounds and start broadening RVX's opportunity base. JMO